Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI

Pathos AI 获得 3.65 亿美元 D 轮融资，通过人工智能推动肿瘤药物开发

NEW YORK, May 15, 2025-- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion.

纽约，2025年5月15日——Pathos AI是一家领先的AI驱动的生物技术公司，致力于将尖端人工智能应用于药物开发，该公司今日宣布完成3.65亿美元的D轮融资，其投后估值约为16亿美元。

This financing marks a major milestone for Pathos as it expands its AI-enabled platform to drive greater speed, precision, and success in oncology drug development. The proceeds will support advancement of the company’s clinical-stage pipeline and continued investment in its proprietary AI Foundation Model purpose-built for oncology..

这笔融资标志着 Pathos 的一个重要里程碑，因其扩展了人工智能赋能的平台，以推动肿瘤药物开发实现更快速度、更高精度和更大成功率。所得资金将用于支持公司临床阶段产品线的推进，并持续投资于其专为肿瘤学构建的专有人工智能基础模型。

As part of this next phase, Pathos is developing the largest multimodal foundation model in oncology. This groundbreaking effort leverages deep clinical, molecular, and imaging data to improve clinical asset selection, clinical trial design, biomarker discovery, and therapeutic innovation across the oncology landscape..

作为这一下一阶段的一部分，Pathos 正在开发肿瘤学领域最大的多模态基础模型。这一开创性的努力利用深入的临床、分子和影像数据，改进整个肿瘤领域的临床资产选择、临床试验设计、生物标志物发现和治疗创新。

'Pathos was founded to transform drug development by harnessing the full potential of multimodal data and AI,' said Iker Huerga, CEO of Pathos AI. 'With this financing, we’re building one of the most advanced AI engines, designed to accelerate development, deepen clinical insight, and ensure the right therapies reach the patients who need them most.'.

“Pathos 的成立旨在通过充分利用多模态数据和人工智能的全部潜力来变革药物开发，”Pathos AI 首席执行官 Iker Huerga 表示。“通过此次融资，我们正在构建最先进的 AI 引擎之一，旨在加速开发进程、深化临床洞察，并确保最需要治疗的患者能够获得合适的疗法。”

Founded to accelerate innovation in oncology, Pathos is pioneering a new model for AI-enabled drug development. One that leverages multimodal data, advanced Artificial Intelligence, and deep clinical insight to bring new therapies to patients faster. With a strong focus on Artificial Intelligence, clinical development, and clinical execution, Pathos is committed to improving patient outcomes by accelerating the path from molecule to medicine..

Pathos成立于加速肿瘤学创新的初衷，正在开创一种人工智能驱动的药物开发新模式。该模式利用多模态数据、先进的人工智能技术和深厚的临床洞察力，以更快地为患者带来新的治疗方法。凭借对人工智能、临床开发和临床执行的高度专注，Pathos致力于通过加速从分子到药物的进程来改善患者的治疗效果。

Contact:

联系：

Business Development: bd@pathos.com

业务发展：bd@pathos.com

Press Inquiries: press@pathos.com

媒体咨询：press@pathos.com